Text Size

Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment

Oddone F, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Holló G; VISIONARY Study Group


  • 2022
  • Advances in Therapy
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Glaucoma Unit, IRCSS-Fondazione Bietti, Rome, Italy; Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK; Instituto Oftalmologico Gomez-Ulla, Calle Maruxa Mallo 3 Santiago de Compostela, Galicia, Spain; LLC Vzglyad, Leningradskaya, Chita, Russia; Santen SA, Geneva, Switzerland; Tutkimusz Ltd, Solymár, Hungary; Eye Center, Prima Medica Health Centers, Budapest, Hungary

Related Publications

MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

Sharif N.A.; Millar J.C.; Zode G.; Ota T.


Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: Two-Year Results from a Randomized, Multicenter Study

Panarelli J.F., Moster M.R., Garcia-Feijoo J., Flowers B.E., Baker N.D., Barnebey H.S., Grover D.S., Khatana A.K., Lee B., Nguyen T., Stiles M.C., Sadruddin O., Khaw P.T., Vold S., McFarland M., Stiles M., Stechschulte A., Strom A., Reynolds A., Noecker R., Thimons J., Khaimi M., Allen E., Sarkisian S., Barnebey H., Golez E., Feldman R., Bell N., Blieden L., Cantor L., WuDunn D., Catoira-Boyle Y., Chen H., Evans J., Martin E., Sozeri Y., Srivastava V., Wise R., Schwartz K., Grover D., Butler M., Emanuel M., Fellman R., Godfrey D., Smith O., Kornmann H., Khatana A., Hagee D., Kuhlman B., Zink J., Moster M., Dale E., Pro M., Baker D., Chambers M., Lehmann D., Caprioli J., Francis B., Giaconi J., Law S., Nouri-Mahdavi K., Coleman A., Flynn W., Rashid E., Reilly C., Rice R., Sidoti P., Panarelli J., Garg R., Tania Tai T.Y., Vinod K., Harizman N., Ritch R., Reiss G., Dewan V., Patel S., Sorenson C., Larsen C., Samuelson T., Hansen M., Barth T., Blakstad A., Buboltz M., Fahmy A., Fahmy M., Montealegre K., Mizener M., Whitted P., Lim M., Brandt J., Baik A., Jiang A., Brown S.V.L., Breunig A.C., Gorla M.S.R., Riss I., Feijoo G., Mendez Hernandez C., Martinez de la Casa J., Dupré Pelaez M., Fernandez Vidal A., García Sáenz S., Morales Fernandez L., Sáenz Francés F., Santos Bueso E., Perucho Gonzalez L., Beckers H.J.M., Kujovic S., Nardi M., Maglionico M.N., Nasini F., Passani A., Strouthidis N., Barton K., Clarke J., Gazzard G., Jayaram H., Khaw P., Papadopoulos M., Puertas R., Toth M., Lunt D., Triolo G., Kam R., Levine J., Flowers B., Nair U., Simmons S., Pokabla M., INN005 Study Group


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022